LataMed AI Corp. (OTC: LMEDD) announced that its 5-for-1 forward stock split has become effective as of the opening of trading on July 15, 2026, following publication on the FINRA Daily List. The forward stock split increases the number of outstanding shares, which may improve marketability and liquidity for shareholders. In conjunction with the split, the company's common stock now trades under the temporary symbol LMEDD, with the 'D' designation expected to remain for approximately 20 business days before reverting to LMED.
The forward stock split is part of a mandatory share exchange that also introduces a new CUSIP number, 21116R404, while the prior CUSIP, 21116R305, has been suspended. Shareholders holding shares through brokerage accounts or in electronic book-entry form are not required to take any action, as the corporate action will be processed automatically. Those holding physical stock certificates are not required to surrender them immediately, but when presented for transfer, sale, or exchange, they will be exchanged for the appropriate number of post-split shares under the new CUSIP.
Dr. Kevin Rodan Levy, CEO of LataMed AI Corp., stated that the forward stock split represents an important corporate milestone. He emphasized the company's focus on expanding its telemedicine platform and pursuing commercialization opportunities for its CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms. The company is a development-stage digital health and AI technology company targeting emerging markets, with an initial focus on Latin America.
The forward stock split does not change the overall value of shareholders' investments, as the number of shares increases proportionally. However, it can make shares more affordable for smaller investors and potentially increase trading activity. The company encourages shareholders with questions to contact their brokerage firm or the company's transfer agent. Additional information is available on the company's website at https://latamed.ai and through its filings with the U.S. Securities and Exchange Commission at www.sec.gov.
This corporate action underscores LataMed AI's efforts to align its capital structure with its strategic growth plans. The company continues to develop technology platforms for healthcare access, patient engagement, provider coordination, emergency response, pharmacy integration, insurance accessibility, payment solutions, and data-driven operations. As a development-stage company, LataMed AI faces risks including the ability to successfully implement its business plan, obtain financing, and achieve regulatory approvals. The forward-looking statements in this announcement are subject to risks and uncertainties that could cause actual results to differ materially.
